PIK3CA mutations occur in 35–40% of HR+/HER2- breast cancers, making it a key driver of tumor growth and therapeutic resistance.
These mutations activate the PI3K/AKT/mTOR pathway, causing cells to grow and spread.
Targeted therapies such as alpelisib and inavolisib are FDA-approved to treat advanced PIK3CA-mutated breast cancer.
It is the most common mutation in metastatic hormone receptor-positive (HR+), HER2-negative breast cancer, occurring in up to 40% of these cases.
The PIK3CA gene encodes a part of the PI3K enzyme.
Mutations act like a “stuck on” switch, forcing cancer cells to proliferate and resist treatment.
Patients with advanced or metastatic HR+/HER2- breast cancer should be tested for this mutation using tumor tissue or liquid biopsy often via the therascreen PIK3CA RGQ PCR Kit.
Prognosis: While sometimes associated with a better prognosis initially, these mutations can lead to resistance to standard hormone therapies.
Targeted Treatment Options Alpelisib (Piqray): Approved in combination with fulvestrant for postmenopausal women and men with HR+/HER2- metastatic breast cancer. Inavolisib (Itovebi): Approved in Oct 2024 in combination with palbociclib and fulvestrant for the same population, showing improved survival outcomes. Capivasertib (Truqap): Approved for tumors with PIK3CA, AKT, or PTEN alterations.
PIK3CA mutations are among the most common actionable alterations in breast cancer, especially in HR-positive/HER2-negative disease, where they occur in roughly 35–40% of cases.
They activate the PI3K/AKT/mTOR pathway and are linked to endocrine resistance, making mutation testing clinically important for treatment selection.
PIK3CA-mutant tumors can behave differently from wild-type tumors, with evidence for poorer response to standard endocrine therapy in advanced disease and a distinct biology that can favor targeted treatment.
Some studies also associate PIK3CA mutations with ER positivity, smaller tumors, and lower grade, so the prognostic signal is not uniform across all settings.
For advanced HR-positive/HER2-negative PIK3CA-mutated breast cancer, PI3K-targeted therapy is now a major option, including the triplet of inavolisib plus palbociclib and fulvestrant, which improved progression-free survival and overall survival .
The most frequent hotspot variants are in the helical and kinase domains, such as E545K and H1047R, which are the classic activating mutations?
These mutations drive downstream signaling that promotes proliferation, survival, and therapy resistance.